Cover Image
市場調查報告書

老化現象:開發平台分析

Ageing - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257825
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
老化現象:開發平台分析 Ageing - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 53 Pages
簡介

老化現象是人類隨著時間變化的現象。老化現象的表徵有體態前彎、便秘、容易受傳染、熱中症和低體溫的風險高、視力低落、皮膚產生明顯皺紋,四周視野衰弱。

本報告提供老化現象的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

老化現象 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Bioo Therapeutics
  • Neuralstem, Inc.
  • RepliCel Life Sciences, Inc.
  • RXi Pharmaceuticals Corporation
  • vida therapeutics inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BIOO-4
  • BIOO-7
  • Drugs for Ageing
  • metformin + sirolimus
  • MG-29
  • MMP-26051
  • MMP-26052
  • NSI-189
  • RCS-01
  • sirolimus
  • Small Molecule for Alzheimer's desease and Ageing
  • TM-5441
  • V-2248

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8574IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ageing - Pipeline Review, H2 2016, provides an overview of the Ageing (Metabolic Disorders) pipeline landscape.

Ageing is the accumulation of changes in a person over time. Symptoms include stooped posture, constipation, and increased susceptibility to infection, risk of heat stroke or hypothermia, decrease in visual acuity, wrinkling and sagging skin, and diminished peripheral vision.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ageing - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ageing (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ageing (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ageing and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively for Ageing.

Ageing (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ageing (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ageing (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ageing (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ageing (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ageing (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ageing (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ageing (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ageing Overview
  • Therapeutics Development
    • Pipeline Products for Ageing - Overview
    • Pipeline Products for Ageing - Comparative Analysis
  • Ageing - Therapeutics under Development by Companies
  • Ageing - Therapeutics under Investigation by Universities/Institutes
  • Ageing - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Ageing - Products under Development by Companies
  • Ageing - Products under Investigation by Universities/Institutes
  • Ageing - Companies Involved in Therapeutics Development
    • Generon (Shanghai) Corporation Ltd.
    • Mapreg S.A.S.
    • RepliCel Life Sciences, Inc.
    • RXi Pharmaceuticals Corporation
    • Saje Pharma, LLC
    • Theravasc, Inc.
  • Ageing - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGS-499 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BQ-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Ageing - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-899 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAP-46 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMP-26051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMP-26052 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCS-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium nitrite SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPL-891.1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ageing - Dormant Projects
  • Ageing - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2016: RepliCel Life Sciences Finishes Enrolment for its Skin Rejuvenation Clinical Trial
      • Dec 17, 2015: RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
      • Sep 15, 2015: RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study
      • Jul 21, 2015: RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
      • Feb 23, 2015: RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial
      • Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ageing, H2 2016
  • Number of Products under Development for Ageing - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Ageing - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
  • Ageing - Pipeline by Mapreg S.A.S., H2 2016
  • Ageing - Pipeline by RepliCel Life Sciences, Inc., H2 2016
  • Ageing - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Ageing - Pipeline by Saje Pharma, LLC, H2 2016
  • Ageing - Pipeline by Theravasc, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ageing - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Ageing, H2 2016
  • Number of Products under Development for Ageing - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top